Literature DB >> 33663537

Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.

Hongyan Wu1, Jing Yang1, Yun-Qiang Liu2, Song Lei3, Mei Yang3, Zhi Yang1, Yuan Yang2, Zhangxue Hu4.   

Abstract

BACKGROUND: Lipoprotein glomerulopathy (LPG) is a rare autosomal dominant kidney disease that is most commonly caused by mutations in ApoE Kyoto (p.R43C) and ApoE Sendai (p.R163P). Differences in phenotype among the various ApoE mutations have been suggested, but the pathogenic role of ApoE Kyoto has not been validated in an animal model. This study intended to establish an ApoE Kyoto murine model and to further compare the pathologic differences between ApoE Kyoto and ApoE Sendai.
METHOD: Male ApoE-deficient mice, 3 months of age, were divided into five groups, including the AD-ApoE Sendai, AD-ApoE Kyoto, AD-ApoE3, AD-eGFP, and ApoE (-/-) groups. The first four groups received recombinant adenovirus that contained the entire coding regions of the human ApoE Sendai and ApoE Kyoto, apoE3, and eGFP genes, respectively. Fasting blood and urine samples were collected at multiple time points. Lipid profiles and urine albumin-creatinine ratio were measured. Renal and aortic histopathologic alterations were analyzed.
RESULTS: After virus injection, plasma human ApoE was detected and rapidly reached the maximum level at 4-6 days in the AD-ApoE Kyoto and AD-ApoE Sendai groups (17.4 ± 3.1 µg/mL vs.: 22.2 ± 4.5 µg/mL, respectively) and at 2 days in the AD-ApoE3 group (38.4 µg/mL). The serum total cholesterol decreased by 63%, 65%, and 73% in the AD-ApoE Kyoto, AD-ApoE Sendai and AD-ApoE3 groups, respectively. There were no significant changes in serum triglyceride and urinary albumin-creatinine ratio among the five groups. Typical lipoprotein thrombi with positive ApoE staining were detected in the AD-ApoE Kyoto and AD-ApoE Sendai groups. The Oil-red O-positive glomerular area tended to be higher in the AD-ApoE Kyoto group (9.2%) than in the AD-ApoE Sendai (3.9%), AD-ApoE3 (4.8%), AD-eGFP (2.9%), and ApoE (-/-) (3.6%) groups. The atherosclerotic plaque area in the aorta was lower in the group injected with various ApoE mutations than in the group without injection of ApoE mutation.
CONCLUSIONS: In this animal study, we first established an ApoE Kyoto mutation murine model and confirmed its pathogenic role in LPG. Our results suggested that LPG may be more severe with the ApoE Kyoto than with the ApoE Sendai.

Entities:  

Keywords:  ApoE Kyoto (p.R43C); ApoE Sendai (p.R163P); Atherosclerosis; Lipoprotein glomerulopathy; Recombinant adenovirus

Mesh:

Substances:

Year:  2021        PMID: 33663537      PMCID: PMC7934380          DOI: 10.1186/s12967-021-02765-x

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  21 in total

Review 1.  Apolipoprotein E-related glomerular disorders.

Authors:  Takao Saito; Akira Matsunaga; Megumu Fukunaga; Kiyotaka Nagahama; Shigeo Hara; Eri Muso
Journal:  Kidney Int       Date:  2019-11-22       Impact factor: 10.612

2.  Chronic graft-versus-host autoimmune disease in Fc receptor gamma chain-deficient mice results in lipoprotein glomerulopathy.

Authors:  Yutaka Kanamaru; Atsuhito Nakao; Isao Shirato; Ko Okumura; Hideoki Ogawa; Yasuhiko Tomino; Chisei Ra
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

3.  Human apolipoprotein E. The complete amino acid sequence.

Authors:  S C Rall; K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1982-04-25       Impact factor: 5.157

4.  A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.

Authors:  A Matsunaga; J Sasaki; T Komatsu; K Kanatsu; E Tsuji; K Moriyama; T Koga; K Arakawa; S Oikawa; T Saito; T Kita; T Doi
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

5.  A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy.

Authors:  Asuka Mitani; Masato Ishigami; Kenji Watase; Tamotsu Minakata; Taku Yamamura
Journal:  J Atheroscler Thromb       Date:  2011-02-16       Impact factor: 4.928

Review 6.  Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.

Authors:  Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2014-02-26       Impact factor: 2.801

7.  Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice.

Authors:  Eyman Osman; Vanessa Evans; Ian R Graham; Takis Athanasopoulos; Jenny McIntosh; Amit C Nathwani; J Paul Simons; George Dickson; James S Owen
Journal:  Atherosclerosis       Date:  2008-09-11       Impact factor: 5.162

8.  Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities.

Authors:  Kenji Ito; Hitoshi Nakashima; Maho Watanabe; Atsunori Ishimura; Yoshito Miyahara; Yasuhiro Abe; Tetsuhiko Yasuno; Masakazu Ifuku; Yoshie Sasatomi; Takao Saito
Journal:  Nephrol Dial Transplant       Date:  2012-08-03       Impact factor: 5.992

9.  Thermodynamic and structural destabilization of apoE3 by hereditary mutations associated with the development of lipoprotein glomerulopathy.

Authors:  Dimitra Georgiadou; Kostas Stamatakis; Eleni K Efthimiadou; George Kordas; Donald Gantz; Angeliki Chroni; Efstratios Stratikos
Journal:  J Lipid Res       Date:  2012-10-30       Impact factor: 5.922

10.  Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.

Authors:  Mingxin Yang; Qinjie Weng; Xiaoxia Pan; Hafiz Muhammad Jafar Hussain; Shuwen Yu; Jing Xu; Xialian Yu; Yunzi Liu; Yuanmeng Jin; Chunli Zhang; Xiao Li; Hong Ren; Nan Chen; Jingyuan Xie
Journal:  Mol Genet Genomic Med       Date:  2020-05-22       Impact factor: 2.183

View more
  1 in total

Review 1.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.